Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Sun Pharma Q4 Results: Drugmaker shares fall after earnings miss; US sales at $459 million
Sun Pharma's US formulations sales fell 1.1% from last year to $459 million during the March quarter. For the full year, the growth was a negative 0.9%.
Aditya Birla Group stocks: Grasim hits new peak; Voda Idea up 46% in 1-mth
Grasim is the flagship company of Aditya Birla Group, which is led by Kumar Mangalam Birla; while, the group holds substantial stake in Vodafone Idea.
Sun Pharma Q4 Preview: Can Unloxcyt and speciality drugs help pharma major deliver another strong quarter?
Sun Pharma is expected to post double-digit revenue growth in Q4FY26, driven by strong performance across speciality drugs, domestic formulations, and emerging markets. Brokerages highlight US portfolio strength, new launches like Unloxcyt, and a steady margin outlook despite higher R&D spending, with EBITDA growth supported by diversified global business momentum outlook
Stocks to Watch for May 21: Aditya Birla Capital, Dr Reddy's Lab, Jubilant Food, Bosch India and more
From Dr Reddy's Laboratories announcing the launch of its oral semaglutide biosimilar in India under the brand name Obeda to Whirlpool of India Ltd reporting a 32.7% year-on-year decline in net profit Q4, here are some stocks to track ahead of Thursday trading session.
Eris Life Q4 Results: Stock gains 12% as Domestic Branded Formulations leads growth
The management of Eris Lifesciences said the phased rollout of the semaglutide portfolio, including pen-based products and obesity-focused SKUs, is expected to support growth momentum going ahead.
Nifty could hit 27,000 once geopolitical tensions ease: Bajaj Finserv AMC CIO
Bajaj Finserv AMC CIO Nimesh Chandan projects 15% earnings growth for Nifty in FY28, with EPS rising to the ₹1,420–1,440 range, making valuations look attractive. He backs metals, construction, and cement as long-term plays on a global supply chain shift, holds gold and silver in the multi-asset portfolio, and flags El Niño and elevated US yields as key risks keeping Indian interest rates high in the near term.
Selling at higher levels turns 23,800 into key barrier for Nifty: Analysts
Benchmark Nifty closed lower last week. Analysts anticipate continued range-bound trading for Nifty this week. Trading strategies suggest buying on dips and selling on rallies within the 23,800-23,200 range. Specific stock recommendations include Indus Towers, Samvardhana Motherson International, Aditya Birla Capital, Sun Pharmaceutical Industries, and Arvind Limited. Investors are advised to consider these opportunities.
Aditya Birla Group to invest $500 million in Vodafone Idea as revival signal strengthens
Aditya Birla Group is injecting ₹4,730 crore into Vodafone Idea (Vi) through a preferential allotment, bolstering the telecom operator's financial standing. This capital infusion follows Kumar Mangalam Birla's return as chairman and aims to support Vi's efforts to compete with rivals Reliance Jio and Bharti Airtel.
Aditya Birla Health bets on wellness incentives to improve claims ratios
Aditya Birla Health wants to reward healthier customers, nudge those on the edge to be more consistent, and, lastly, intervene with high-risk customers to help them manage their health.
Gold loans power Small Finance Banks' growth as microfinance asset quality weakens
Small Finance Banks are shifting focus to secured loans like gold loans. This move aims to stabilize their financial health and earnings. The unsecured microfinance sector continues to face high bad loan ratios. This strategic pivot is happening as regulators encourage diversification. Some larger banks are also growing their microfinance business. This change is crucial for long-term stability and growth.
Health insurance share rises to 41% of non-life industry in FY26
Health insurance strengthened its position as the largest segment in India’s non-life insurance industry in FY26, with its share rising to 40.8% from 38.6% a year earlier. The segment grew 15.4% to about Rs 1.4 lakh crore, outpacing the overall non-life industry growth of 9.3%, which took total gross direct premium income close to Rs 3.4 lakh crore.
Aditya Birla Capital Q4 FY26 Results | Wockhardt Q4 FY26 Results | Top Buzzing Stocks Today - Equitymaster
Aditya Birla Capital Q4 FY26 Results | Wockhardt Q4 FY26 Results | Top Buzzing Stocks TodayEquitymaster